Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anthrax and plague DNA vaccine
- Development stage
- Unknown
- Lead developer
- U.S. Army Medical Research Institute of Infectious Diseases
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The anthrax and plague DNA vaccine is a multivalent biodefense candidate developed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to provide simultaneous protection against *Bacillus anthracis* and *Yersinia pestis*. The vaccine typically utilizes a combination of DNA plasmids, such as pV-PA (encoding the anthrax Protective Antigen) and pV-F1/V (encoding a fusion of the plague F1 and V antigens). The mechanism of action involves the delivery of these plasmids into host cells—often facilitated by a needle-free jet injector or gene gun—where the host's cellular machinery expresses the bacterial antigens. This process elicits a robust immune response, including the production of neutralizing antibodies that target the anthrax toxin and the plague bacterium's virulence factors. This DNA-based platform offers advantages in terms of stability, ease of manufacturing, and safety compared to traditional live-attenuated or protein-based vaccines.
- Other names
- Anthrax/Plague DNA vaccineMulti-agent DNA vaccine for anthrax and plague
02
Targets
F1 antigen (F1 capsular antigen)LcrV (V antigen)PA (Influenza polymerase acidic protein)
Beyond the preview
Go deeper on anthrax and plague DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anthrax and plague DNA vaccine.